SCHEMBL632357

SCHEMBL632357

O=C(Nc1ccc(Cl)cc1)c1sccc1NCc1ccnc2ccccc12

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 7/20 0.73
KIT P10721 2/20 0.73
RAF1 P04049 1/20 0.73
LCK P06239 1/20 0.73
RET P07949 1/20 0.73
CYP3A4 P08684 1/20 0.73
MAP3K20 Q9NYL2 1/20 0.73
RIPK3 Q9Y572 1/20 0.73
FLT1 P17948 4/20 0.62
ADORA2A P29274 1/20 0.46
IDO1 P14902 2/20 0.46
RAB9A P51151 1/20 0.44
DNMT1 P26358 1/20 0.44
DNMT3L Q9UJW3 1/20 0.44
DNMT3A Q9Y6K1 1/20 0.44
MAPK8 P45983 1/20 0.44
MAPK9 P45984 1/20 0.44
MAPK10 P53779 1/20 0.44
ALDH1A1 P00352 1/20 0.42
MEN1 O00255 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4851882 0.90 KDR (0.61) KDRKITRAF1LCKRET
SCHEMBL5792910 0.90 KDR (0.73) KDRKITRAF1LCKRET
SCHEMBL5792923 0.90 KDR (0.73) KDRKITRAF1LCKRET
SCHEMBL14066606 0.87 KDR (0.81) KDRKITRAF1LCKRET
SCHEMBL14044899 0.86 KDR (0.69) KDRKITRAF1LCKRET
SCHEMBL14044816 0.86 KDR (0.69) KDRKITRAF1LCKRET
SCHEMBL14076809 0.86 KDR (0.80) KDRKITRAF1LCKRET
SCHEMBL5792920 0.85 KDR (0.68) KDRKITRAF1LCKRET
Osi-930 SCHEMBL29352171 0.85 KDR (1.00) KDRKITRAF1LCKRET
Osi-930 SCHEMBL633719 0.85 KDR (1.00) KDRKITRAF1LCKRET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1590328-B1 (2-CARBOXAMIDO) (3-AMINO) THIOPHENE COMPOUNDS OSI PHARM INC (US) 2012-02-22 EP claimed
WO-2010088000-A2 ANTIFIBROTIC COMPOUNDS AND USES THEREOF ANGION BIOMEDICA CORP. (US) 2010-08-05 WO claimed
CN-100471841-C (2-carboxamido) (3-amino) thiophene compounds OSI PHARM INC (US) 2009-03-25 CN claimed
CN-1723200-A (2-carboxamido) (3-amino) thiophene compounds OSI PHARM INC (US) 2006-01-18 CN claimed
US-6949563-B2 (2-carboxamido)(3-amino)thiophene compounds OSI PHARMACEUTICALS, INC. 2005-09-27 US claimed
US-20040186124-A1 (2-carboxamido)(3-amino)thiophene compounds OSI PHARMACEUTICALS, INC. 2004-09-23 US claimed
EP-1590328-B1 (2-CARBOXAMIDO) (3-AMINO) THIOPHENE COMPOUNDS OSI PHARM INC (US) 2012-02-22 EP disclosed
WO-2010088000-A2 ANTIFIBROTIC COMPOUNDS AND USES THEREOF ANGION BIOMEDICA CORP. (US) 2010-08-05 WO disclosed
US-7696225-B2 (2-carboxamido)(3-Amino) thiophene compounds OSI PHARMACEUTICALS, INC. (US) 2010-04-13 US disclosed
US-7524859-B2 (2-carboxamido)(3-amino)thiophene compounds OSI PHARMACEUTICALS, INC. (US) 2009-04-28 US disclosed
CN-100471841-C (2-carboxamido) (3-amino) thiophene compounds OSI PHARM INC (US) 2009-03-25 CN disclosed
CN-101087782-A (2-carboxamido)(3-amino) thiophene compounds OSI PHARM INC (US) 2007-12-12 CN disclosed
EP-1590328-A4 (2-CARBOXAMIDO) (3-AMINO) THIOPHENE COMPOUNDS OSI PHARM INC (US) 2007-09-19 EP disclosed
CN-1723200-A (2-carboxamido) (3-amino) thiophene compounds OSI PHARM INC (US) 2006-01-18 CN disclosed
EP-1590328-A2 (2-CARBOXAMIDO) (3-AMINO) THIOPHENE COMPOUNDS OSI Pharmaceuticals, Inc. (US) 2005-11-02 EP disclosed
US-6949563-B2 (2-carboxamido)(3-amino)thiophene compounds OSI PHARMACEUTICALS, INC. 2005-09-27 US disclosed
US-20050192320-A1 (2-Carboxamido)(3-amino)thiophene compounds CREW ANDREW P (US) 2005-09-01 US disclosed
US-20050154014-A1 (2-carboxamido)(3-amino) thiophene compounds OSI PHARMACEUTICALS, INC. 2005-07-14 US disclosed
US-20040186124-A1 (2-carboxamido)(3-amino)thiophene compounds OSI PHARMACEUTICALS, INC. 2004-09-23 US disclosed
WO-2004063330-A2 (2-CARBOXAMIDO) (3-AMINO) THIOPHENE COMPOUNDS OSI PHARMACEUTICALS, INC. (US) 2004-07-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040186124-A1 (2-carboxamido)(3-amino)thiophene compounds ABL1, NAT1, KRAS KDR 869/4885KIT 1833/4885RAF1 649/4885
US-20050154014-A1 (2-carboxamido)(3-amino) thiophene compounds AADAC, PAM, TPMT KDR 2418/4885KIT 4457/4885RAF1 3013/4885
US-20050192320-A1 (2-Carboxamido)(3-amino)thiophene compounds PCNA, MKI67, TPMT KDR 1769/4885KIT 289/4885RAF1 406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.